Tau PET and Plasma <i>p</i> ‐tau217 as Independent and Synergistic Predictors of Clinical Progression in Early Symptomatic AD Patients With Amyloid and Tau Pathology

Patients with both higher baseline Tau PET and p-tau217 showed a statistically significant clinical worsening at Week 76 compared with those with both lower baseline Tau PET and p-tau217. Results suggest that, although baseline values of tau PET imaging and p-tau217 alone predicted clinical worsening at Week 76, using both tau PET and p-tau217 provided a better prognostic value than tau PET or p-tau217 alone in patients with early symptomatic AD.